We serve Chemical Name:2,6-Difluoro-4-hydroxybenzaldehyde CAS:532967-21-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,6-Difluoro-4-hydroxybenzaldehyde
CAS.NO:532967-21-8
Synonyms:Benzaldehyde, 2,6-difluoro-4-hydroxy-;VHR DQ BF FF;2,6-Difluoro-4-hydroxybenzaldehyde
Molecular Formula:C7H4F2O2
Molecular Weight:158.102
HS Code:2913000090
Physical and Chemical Properties:
Melting point:179-182℃
Boiling point:252.6±35.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.559
PSA:37.30000
Exact Mass:158.017929
LogP:2.52
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzaldehyde, 2,6-difluoro-4-hydroxy- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-Difluoro-4-hydroxybenzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,VHR DQ BF FF Use and application,2,6-Difluoro-4-hydroxybenzaldehyde technical grade,usp/ep/jp grade.
Related News: This scheme also stipulates minimum domestic value addition in different target segments. Fermentation based products should have at least 90% and chemical synthesis based products should have at least 70% domestic content to qualify for the benefits. N-(2-Chlorophenyl)-2-cyanoacetamide manufacturers CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up. Boc-D-4-Cyanophenylalanine suppliers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. 2-(4-benzylpiperazin-1-yl)-4-bromobenzaldehyde vendor & factory This scheme also stipulates minimum domestic value addition in different target segments. Fermentation based products should have at least 90% and chemical synthesis based products should have at least 70% domestic content to qualify for the benefits. ,CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up.
